Clinical trial
Drug Use Investigation of Regorafenib/ STIVARGA for Unresectable, Metastatic or Recurrent Colorectal Cancer
NCT01843400 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Drug Use Investigation of Regorafenib/ STIVARGA for Unresectable, Metastatic or Recurrent Colorectal Cancer
- Lead sponsor
- Bayer
- Phase
- Observational
- Overall status
- Completed
- Start date
- April 22, 2013
- Completion date
- November 14, 2016
- Enrollment
- 1,301 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.